Bioinspired cardiac-targeted metal-organic framework nanozyme for modulating inflammatory responses in heart failure with preserved ejection fraction
This study develops a novel cardiac-targeted nanozyme that effectively ameliorates key pathologies in experimental HFpEF. Its therapeutic action involves a dual mechanism: direct ROS scavenging and modulation of the SOCS3-IRS1-AKT2 signaling axis to improve insulin resistance. These findings highlight the potential of multifunctional nanozymes as a promising strategy for tackling the complex pathophysiology of HFpEF.
Authors
- Y Wang
- Xiaolei Cheng
- Yingchao Shi (ORCID: https://orcid.org/0000-0002-4694-0159)
- Yu Han (ORCID: https://orcid.org/0000-0002-5910-6307)
- Jia Shen (ORCID: https://orcid.org/0009-0007-0175-2836)
- Zhen Li (ORCID: https://orcid.org/0000-0002-6328-3314)
- Yuesheng Gui (ORCID: https://orcid.org/0009-0004-9345-3275)
- Zhiyuan Niu
- Junyue Xing
- Hao Tang
- Weining Yuan
- Xiaowan Fan
- Kairui Xiao
Institutions
- National Health and Family Planning Commission (CN)
- Henan University of Technology (CN)
- Zhengzhou University (CN)
- Henan University of Engineering (CN)
- California Medical Innovations Institute (US)
- Henan Provincial People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Bioengineering and Biotechnology
- Published
- 2026-02-12
- DOI
- https://doi.org/10.3389/fbioe.2026.1744643
- Primary Topic
- Advanced Nanomaterials in Catalysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China